Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 15 Apr 2024
One-third of patients experience responses when using adagrasib plus cetuximab, with a median overall survival of 15 points 9 months.
Read Full NewsFindings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
1.
Talquetamab Regimens Boost Survival in Multiple Myeloma
2.
Enhanced CAR T cell therapy offers new strategy for lymphoma
3.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
4.
How Social Determinants of Health Are Linked to Outcomes in Multiple Myeloma
5.
Aspirin for CRC Risk Reduction May Benefit Unhealthy People Most
1.
Examining Serum Osmolality: What It Is And How To Test For It
2.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
3.
Exploring the Mystery of Angiokeratomas on Scrotum: Causes, Symptoms and Treatment
4.
Managing Supportive Care During Platelet Recovery
5.
Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge